Identification, characterization, and targeting of IL-4 receptor by IL-4-pseudomonas exotoxin in mouse models of anaplastic thyroid cancer

Discovery Medicine

Volumn 20, Issue 111, 2015, Pages 273-284

  Joshi, Bharat H ^a   Suzuki, Akiko ^a   Fujisawa, Toshio ^a   Leland, Pamela ^a   Varrichio, Frederick ^b   Lababidi, Samir ^b   Lloyd, Ricardo ^b   Kasperbauer, Jan ^b   Puri, Raj K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; IODINE 125; MESSENGER RNA; PSEUDOMONAS EXOTOXIN; BACTERIAL TOXIN; EXOTOXIN; HYBRID PROTEIN; IL4 PROTEIN, HUMAN; IL4R PROTEIN, HUMAN; INTERLEUKIN 4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; TUMOR PROTEIN; VIRULENCE FACTOR;

ADOLESCENT; ADULT; AGED; ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION ASSAY; CELL PROLIFERATION; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR BIOPSY; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; YOUNG ADULT; AGONISTS; ANIMAL; DRUG DELIVERY SYSTEM; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; THYROID NEOPLASMS; TUMOR CELL LINE;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; EXOTOXINS; FEMALE; HUMANS; INTERLEUKIN-4; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; THYROID NEOPLASMS; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949783108     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Agresti A. A Survey of Exact Inference for Contigency Tables. Stat Sci 7:131-177, 1992.
2. Agresti A. Categorical Data Analysis. John Wiley and Sons, New York, NY, USA, 2002.
3. Ain KB, Egorin MJ, Desimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10(7):587-594, 2000.
4. Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, Chouaib S, Mami-Chouaib F. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 77(1):7-12, 1998.
5. Burt BM, Bader A, Winter D, Rodig SJ, Bueno R, Sugarbaker DJ. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res 18(6):1568-1577, 2012.
6. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208(3):469-478, 2011.
7. Denardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16(2):91-102, 2009.
8. Garland L, Gitlitz B, Ebbinghaus S, Pan H, De Haan H, Puri RK, Von HoffD, Figlin R. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother 28(4):376-381, 2005.
9. Gimm O. Thyroid cancer. Cancer Lett 163(2):143-156, 2001.
10. Hosmer DW, Lemeshow S. Applied Logistic Regression. John Wiley and Sons, Inc., Hoboken, NJ, USA, 2000.
11. Husain SR, Gill P, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Mol Med 3(5):327-338, 1997.
12. Husain SR, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med 5(7):817-822, 1999.
13. Joshi BH, Leland P, Asher A, Prayson RA, Varricchio F, Puri RK. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res 61(22):8058-8061, 2001.
14. Joshi BH, Leland P, Calvo A, Green JE, Puri RK. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy. Cancer Res 68(22):9311-9317, 2008a.
15. Joshi BH, Leland P, Lababidi S, Varrichio F, Puri RK. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease. Cancer Med 3(6):1615-1628, 2014.
16. Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, Gilbertson RJ, Puri RK, Consortium USPBT. Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro Oncol 10(3):265-274, 2008b.
17. Kawakami K, Leland P, Puri RK. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res 60(11):2981-2987, 2000.
18. Kawakami M, Kawakami K, Puri RK. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 65(1):15-25, 2003.
19. Kioi M, Takahashi S, Kawakami M, Kawakami K, Kreitman RJ, Puri RK. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. Cancer Res 65(18):8388-8396, 2005.
20. Kobayashi M, Kobayashi H, Pollard RB, Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160(12):5869-5873, 1998.
21. Li Z, Chen L, Qin Z. Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol 6(6):415-422, 2009.
22. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, Fong Y, Wong RJ. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab 93(11):4403-4407, 2008.
23. Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 238(1):90-94, 1997.
24. Murata T, Taguchi J, Puri RK. Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood 91(10):3884-3891, 1998.
25. Murata T, Taguchi J, Puri RK, Mohri H. Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system. Int J Hematol 69(1):13-20, 1999.
26. Nakagomi H, Pisa P, Pisa EK, Yamamoto Y, Halapi E, Backlin K, Juhlin C, Kiessling R. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 63(3):366-371, 1995.
27. Obiri NI, Leland P, Murata T, Debinski W, Puri RK. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol 158(2):756-764, 1997.
28. Obiri NI, Puri RK. Characterization of interleukin-4 receptors expressed on human renal cell carcinoma cells. Oncol Res 6(9):419-427, 1994.
29. Puri RK. Structure and function of interleukin-4 and its receptor. Cancer Treat Res 80:143-185, 1995a.
30. Puri RK. Structure and Function of Interleukin-4 and its Receptors. Kluwer Academic Publishers, Norwell, MA, USA, 1995b.
31. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, Kreitman RJ. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 56(24):5631-5637, 1996a.
32. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, Pastan I, Debinski W. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87(10):4333-4339, 1996b.
33. Puri RK, Leland P, Obiri NI, Husain SR, Mule J, Pastan I, Kreitman RJ. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. Cell Immunol 171(1):80-86, 1996c.
34. Puri RK, Ogata M, Leland P, Feldman GM, Fitzgerald D, Pastan I. Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. Cancer Res 51(11):3011-3017, 1991.
35. Puri S, Joshi BH, Sarkar C, Mahapatra AK, Hussain E, Sinha S. Expression and structure of interleukin 4 receptors in primary meningeal tumors. Cancer 103(10):2132-2142, 2005.
36. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913-2921, 2014.
37. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6(6):2157-2165, 2000.
38. Rosai J, Saxen EA, Woolner L. Undifferentiated and poorly differentiated carcinoma. Semin Diagn Pathol 2(2):123-136, 1985.
39. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 105(2):344-352, 1996.
40. Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res 67(20):9903-9912, 2007.
41. Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21(3):339-359, 1999.
42. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer 65(1):5-29, 2015.
43. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesu G, De Maria R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63(20):6784-6790, 2003.
44. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre S, Di Gesu G, De Maria R, Stassi G. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 66(3):1491-1499, 2006.
45. Vella V, Mineo R, Frasca F, Mazzon E, Pandini G, Vigneri R, Belfiore A. Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease. J Clin Endocrinol Metab 89(6):2880-2889, 2004.
46. Venmar KT, Carter KJ, Hwang DG, Dozier EA, Fingleton B. IL4 receptor ILR4alpha regulates metastatic colonization by mammary tumors through multiple signaling pathways. Cancer Res 74(16):4329-4340, 2014.
47. Venmar KT, Fingleton B. Lessons from immunology: IL4R directly promotes mammary tumor metastasis. Oncoimmunology 3(9):e955373, 2014.
48. Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol 3(7):407-414, 2002.
49. Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S,. Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, Hingorani VN, Puri RK. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 64(1-2):125-137, 2003.
50. Whitehead RP, Unger JM, Goodwin JW, Walker MJ, Thompson JA, Flaherty LE, Sondak VK. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. J Immunother 21(6):440-446, 1998.
51. Zelba H, Weide B, Martens A, Derhovanessian E, Kini Bailur J, Kyzirakos C, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, De Vries IJ, Sucker A, Schadendorf D, Buttner P, Garbe C, Pawelec G. Circulating CD4+ T-cells that produce IL-4 or IL-17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of stage IV melanoma patients. Clin Cancer Res 20(16):4390-4399, 2014.